申请人:Andersson Carl-Magnus
公开号:US20060094758A1
公开(公告)日:2006-05-04
Disclosed herein are compounds of Formula I,
or a pharmaceutically acceptable salt, amide, ester, or prodrug thereof. Also disclosed are methods of inhibiting an activity of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an effective amount of one or more of the compounds of Formula I. Disclosed are also methods of inhibiting an activation of a monoamine receptor comprising contacting the monoamine receptor or a system containing the monoamine receptor with an effective amount of one or more of the compounds of Formula I. Furthermore, methods of treating psychotic disease using a compound of Formula I are disclosed.
本文披露了公式I的化合物,或其药学上可接受的盐、酰胺、酯或前药。还披露了抑制单胺受体活性的方法,包括将单胺受体或含有单胺受体的系统与公式I的一种或多种化合物的有效量接触。还披露了抑制单胺受体激活的方法,包括将单胺受体或含有单胺受体的系统与公式I的一种或多种化合物的有效量接触。此外,本文还披露了使用公式I的化合物治疗精神疾病的方法。